Tubulin/HDAC-IN-1

Tubulin/HDAC-IN-1 是一种双重 tubulin 和 HDAC-IN-1 抑制剂,通过 CH/π 相互作用与 tubulin 结合、通过氢键相互作用与 HDAC8 结合而发挥功能,可抑制 tubulin 聚合并选择性抑制 HDAC8 (IC50: 150 nM),对各种人类癌细胞具有细胞毒性,还能将细胞周期阻滞在 G2/M 期并诱导细胞凋亡 (apoptosis),可用于神经母细胞瘤、白血病等血液肿瘤和实体肿瘤的研究。
产品编号: MS-W00780 CAS No.: 2413587-26-3 分子式: C21H18N4O3 分子量: 374.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Tubulin/HDAC-IN-1 是一种双重 tubulin 和 HDAC-IN-1 抑制剂,通过 CH/π 相互作用与 tubulin 结合、通过氢键相互作用与 HDAC8 结合而发挥功能,可抑制 tubulin 聚合并选择性抑制 HDAC8 (IC50: 150 nM),对各种人类癌细胞具有细胞毒性,还能将细胞周期阻滞在 G2/M 期并诱导细胞凋亡 (apoptosis),可用于神经母细胞瘤、白血病等血液肿瘤和实体肿瘤的研究。

生物实验数据

生物活性 Tubulin/HDAC-IN-1 is a dual tubulin and HDAC-IN-1 inhibitor that functions through CH/π interactions with tubulin and hydrogen-bonding interactions with HDAC8, inhibits tubulin polymerization and selectively inhibits HDAC8 (IC50: 150 nM), exhibits cytotoxicity against various human cancer cells, induces cell cycle arrest at G2/M phase and apoptosis (apoptosis), and can be used for research on hematological malignancies such as neuroblastoma and leukemia as well as solid tumors.
IC50 & Target HDAC6:1 μM, HDAC8:150 nM, HDAC11:1.9 μM
体外研究
(In Vitro)

Tubulin/HDAC-IN-1 (Compound 12a, 72 h) shows cytotoxicity against various human cancer cell lines with an averaged IC50 value of 0.6 nM.
Tubulin/HDAC-IN-1 (2 nM, 24 h) induces HT29 cell cycle arrest in the G2/M phase and produces caspase-induced apoptosis of HT29 cells through mitochondrial dysfunction.
Tubulin/HDAC-IN-1 selectively inhibits HDAC8 (IC50: 150 nM), inhibits HDAC6 and HDAC11 with IC 50 values of 1 μM and 1.9 μM respectively.
Tubulin/HDAC-IN-1 (0.5-100 nM, 24 h/30 min) dose-dependently increases γH2AX level and acetylated SMC3 in HT-29 cells.
Tubulin/HDAC-IN-1 (5-15 μΜ, 0-40 min) inhibits tubulin polymerization in a dose-dependent manner, with a maximal effect achieved at 10 μM.
Tubulin/HDAC-IN-1 (250 nM, 30 min) depolymerizes the cell microtubule network, and the effect is not specific.
Tubulin/HDAC-IN-1 shows good in vitro metabolic stability expressed by the intrinsic clearance CLint (given in μL/min/mg protein) using rat liver microsomes (RLM) and human liver microsomes (HLM).

Compound RLM RLM HLM HLM
t1/2 (h) CLint t1/2 CLint
Tubulin/HDAC-IN-1 6.6 1.75 32 0.36

Cell Proliferation Assay

Cell Line: Various tumor cell lines as below
Concentration:
Incubation Time: 72 h
Result: Activities of Tubulin/HDAC-IN-1 (Compound 12a) against various tumor cell lines (IC50 nM):
NCIN87 K562 K562R MiaPaca2 SKOV3 A549 MCF-7 MDA-MB-231 HCT116 HT-29
Tubulin/HDAC-IN-1 0.1 0.35 0.56 0.94 0.6 0.84 0.78 0.7 0.6 0.62

Western Blot Analysis

Cell Line: HT-29 cells
Concentration: 0.5, 1, 5, 10 nM for γH2AX; 0.5, 1, 100 nM for acetylated SMC3
Incubation Time: 24 h for γH2AX, 30 min for acetylated SMC3
Result: Dose-dependently increased γH2AX level and acetylated SMC3.
体内研究
(In Vivo)

Tubulin/HDAC-IN-1 (Compound 12a, intratumoral injection, 0.25 mg/kg, three times a week for two weeks) decreases MCA205 tumor growth and extends the overall survival of treated mice in allogeneic sarcoma mice model.

Animal Model: Allogeneic sarcoma model in C57BL/6 mice
Dosage: 0.1, 0.25, 0.50 mg/kg, three times a week for two weeks.
Administration: Intratumoral injection
Result: Decreased tumor growth and extended the overall survival of treated mice with no obvious side effects.

化学信息

分子量 374.39
分子式 C21H18N4O3
CAS No. 2413587-26-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础